explore -WSS

explore

author：leisure time 2025-09-03 03:24:22 - browse：4

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： STAT Wunderkinds: Ruey Hu's digital tools for parsing research

WSS

Sanders adds drug shortage policies to pandemic preparedness bill

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Group opposing PBM reform sets lobbying record

How dance can help nurses traumatized by Covid

Hospitals warn Medicare's drug payment fix is ‘unlawful’

focus

explore

Wikipedia

The cancer drug shortage isn’t new — and neither are the solutions

Senate panel to vote on hospitals, PBMs, prisoner care

Virginia high school admissions case could be legal follow

In early work, researchers turn to CRISPR to treat Alzheimer's

Duchenne breakthrough therapy leaves behind pioneering families

Listen: Wegovy in the brain & pivotal Alzheimer's data

United colonoscopy coverage change 'may cost lives,' doctors say

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

How to save PrEP access — and even expand it

Readout Newsletter: New research from Sanofi, Regeneron, etc.

entertainment

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

WHO calls for emergency meeting on new China virus, as cases spread

Medicare has a new plan to address drug shortages

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

WHO calls for emergency meeting on new China virus, as cases spread

leisure time

hotspot

focus

explore